Botulinum toxin treatment
Botulinum toxin (BoNT) injections are the first-line treatment for most focal dystonias — cervical dystonia (wry neck), blepharospasm (involuntary eyelid closure), oromandibular dystonia (jaw and facial muscle involvement), adductor laryngeal dystonia (spasmodic dysphonia) and task-specific dystonias (writer’s cramp, musician’s dystonia). BoNT works by blocking acetylcholine release at the neuromuscular junction, producing targeted, temporary weakness of the overactive muscles responsible for the abnormal postures. The effect typically begins within 2–5 days, peaks at 2–4 weeks and lasts 3–4 months, requiring repeat injections for sustained benefit.
Accurate muscle selection is the critical determinant of treatment efficacy. In cervical dystonia, for example, the sternocleidomastoid, trapezius, splenius capitis, levator scapulae and scalene muscles may be involved individually or in combination, and injection patterns must be tailored to the specific head posture (rotation, lateral flexion or extension). Electromyography (EMG) guidance helps confirm correct muscle identification, particularly for deep or anatomically complex muscles. Doses must be carefully calibrated — excessive dose causes unwanted weakness (dysphagia in cervical dystonia, ptosis in blepharospasm); insufficient dose provides inadequate relief. At Kathmandu Neurology Clinic & Cognitive Center, Dr. Jitendra Prasad Yadav (NMC 8029) performs BoNT injections with clinical guidance, selecting muscles based on detailed examination of the dystonic pattern and adjusting doses and injection sites at each follow-up visit to optimise response.
- First-line for focal dystonia: cervical, blepharospasm, oromandibular, laryngeal
- Blocks acetylcholine release at neuromuscular junction
- Effect begins 2–5 days, peaks 2–4 weeks, lasts 3–4 months
- Accurate muscle selection critical for efficacy
- EMG guidance for deep or complex muscles
- Dose calibration to avoid unwanted weakness
Related: Neurologist Kathmandu → · Dr. Jitendra Knowledge Hub → · ICHD-3 Topic →
Medication options for generalised dystonia
Generalised dystonia affecting multiple body regions requires systemic medication in addition to or instead of BoNT injections. Oral medications include anticholinergics (trihexyphenidyl, benztropine), which are most effective in younger patients and may require slow dose escalation to minimise side effects (dry mouth, blurred vision, constipation, cognitive effects). Baclofen (oral or intrathecal) reduces dystonic spasms and is particularly useful when spasticity coexists. Clonazepam and diazepam provide relief in some patients but carry sedation and dependence risk. Tetrabenazine and deutetrabenazine (VMAT2 inhibitors) may reduce dystonia in certain conditions, particularly tardive dystonia.
For treatment-resistant generalised dystonia, deep brain stimulation (DBS) of the globus pallidus interna (GPi) is an established surgical option. DBS is most effective in primary generalised dystonia (especially DYT1-positive genetically confirmed cases) and in tardive dystonia, with response rates of 60–80% in carefully selected patients. Improvement may continue over 6–12 months after implantation. The decision to proceed with DBS requires comprehensive pre-surgical evaluation including assessment of functional impairment, cognitive and psychiatric status, and realistic expectation setting. Dr. Jitendra Prasad Yadav (NMC 8029) provides neurological assessment and medication management for dystonia at Kathmandu Neurology Clinic & Cognitive Center, Durbar Marg, Opposite of Yak & Yeti Hotel, with referral for specialist surgical evaluation when appropriate.
- Anticholinergics (trihexyphenidyl, benztropine) — most effective in younger patients
- Baclofen (oral or intrathecal) — dystonic spasms, coexisting spasticity
- Clonazepam/diazepam — relief in some, sedation and dependence risk
- VMAT2 inhibitors (tetrabenazine, deutetrabenazine) — tardive dystonia
- Deep brain stimulation (GPi) — treatment-resistant generalised dystonia